Blaine Eldred
DownloadHi-Res Photo
About
Copy Link
Biography
Blaine Eldred is an aspiring physician-scientist dedicated to the study and treatment of brain cancer. He graduated from UCLA in 2019 with a degree in neuroscience and a minor in biomedical research, where he developed a strong interest in cancer biology and translational medicine. After graduation, he was hired by Dr. Albert Lai as a laboratory manager and contributed to a variety of interdisciplinary research projects until 2025. Blaine’s long-term goal is to become an academic physician-scientist focused on advancing the understanding of brain tumors and developing more effective treatments for patients.
Last Updated on June 25, 2025.
Education & Training
- BS
- UCLA, Neuroscience (2019)
Research
Copy Link
Overview
Blaine Eldred is a physician-scientist trainee specializing in neuro-oncology and translational cancer research. At UCLA, Blaine contributed to numerous interdisciplinary projects that leveraged imaging, pathology, and molecular profiling to better understand tumor biology and therapeutic response in diffuse gliomas.
ORCID
0000-0002-3351-3895
Research at a Glance
Publications Timeline
A big-picture view of Blaine Eldred's research output by year.
16Publications
149Citations
Publications
Featured Publications
D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
Pianka S, Li T, Prins T, Eldred B, Kevan B, Liang H, Rinonos S, Kornblum H, Nathanson D, Pellegrini M, Liau L, Nghiemphu P, Cloughesy T, Lai A. D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation. Cancer Research Communications 2024, 4: 876-894. PMID: 38445960, PMCID: PMC10959073, DOI: 10.1158/2767-9764.crc-23-0271.Peer-Reviewed Original ResearchCitationsAltmetricdCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma
Zapanta Rinonos S, Li T, Pianka S, Prins T, Eldred B, Kevan B, Liau L, Nghiemphu P, Cloughesy T, Lai A. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma. Journal Of Neuro-Oncology 2024, 166: 129-142. PMID: 38224404, PMCID: PMC10824881, DOI: 10.1007/s11060-023-04531-z.Peer-Reviewed Original ResearchCitationsAltmetricPrognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
Lam K, Eldred B, Kevan B, Pianka S, Eldred B, Rinonos S, Yong W, Liau L, Nghiemphu P, Cloughesy T, Green R, Lai A. Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas. Neuro-Oncology Advances 2022, 4: vdac030. PMID: 35386566, PMCID: PMC8982195, DOI: 10.1093/noajnl/vdac030.Peer-Reviewed Original ResearchCitationsAltmetricTargeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience
Ji M, Eldred B, Liu R, Pianka S, Molaie D, Kevan B, Pan S, Lai T, Nguyen N, Chow F, Yong W, Cox C, Reeh D, Li T, Liau L, Nghiemphu P, Cloughesy T, Li G, Lai A. Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience. Neuro-Oncology Advances 2020, 2: vdaa009. PMID: 32118206, PMCID: PMC7034640, DOI: 10.1093/noajnl/vdaa009.Peer-Reviewed Original ResearchCitationsAltmetric
2026
MGMT downregulation by CRISPR/Cas13 RNA-guided RNA targeting enhances glioma cell sensitivity to TMZ chemotherapy
Prins T, Lai T, Li T, Fisher A, Eldred B, Mostafavi R, Liau L, Chong R, Nghiemphu P, Cloughesy T, Nathanson D, Lai A. MGMT downregulation by CRISPR/Cas13 RNA-guided RNA targeting enhances glioma cell sensitivity to TMZ chemotherapy. Journal Of Neuro-Oncology 2026, 177: 48. PMID: 41817895, PMCID: PMC12982228, DOI: 10.1007/s11060-026-05500-y.Peer-Reviewed Original ResearchAltmetricMeSH KeywordsAntineoplastic Agents, AlkylatingBrain NeoplasmsCell Line, TumorCell SurvivalCRISPR-Cas SystemsDacarbazineDNA Modification MethylasesDNA Repair EnzymesDown-RegulationDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticGliomaHumansRNA, Guide, CRISPR-Cas SystemsRNA, MessengerTemozolomideTumor Suppressor ProteinsA single-institution retrospective study of multicentric gliomas stratified by IDH mutational status
Yang C, Mostafavi R, Le C, Fisher A, Eldred B, Prins T, Lai T, Liau L, Everson R, Chong R, Nghiemphu P, Cloughesy T, Ellingson B, Lai A. A single-institution retrospective study of multicentric gliomas stratified by IDH mutational status. Neuro-Oncology Advances 2026, 8: vdag047. PMID: 42116936, PMCID: PMC13157338, DOI: 10.1093/noajnl/vdag047.Peer-Reviewed Original ResearchAltmetricClinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab
Le C, Sanvito F, Yang C, Eldred B, Raymond C, Prins T, Fisher A, Li T, Liau L, Chong R, Nghiemphu P, Cloughesy T, Lai A, Ellingson B. Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab. Neuro-Oncology Advances 2026, 8: vdag089. PMID: 42046772, PMCID: PMC13110796, DOI: 10.1093/noajnl/vdag089.Peer-Reviewed Original Research
2025
Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas
Cho N, Le V, Teraishi A, Liu V, Sanvito F, Telesca D, Nakajo M, Wang C, Oshima S, Eldred B, Yao J, Nghiemphu P, Salamon N, Cloughesy T, Lai A, Ellingson B. Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas. Neuro-Oncology 2025, 27: 3306-3317. PMID: 40888039, PMCID: PMC12916721, DOI: 10.1093/neuonc/noaf171.Peer-Reviewed Original ResearchCitationsAltmetricAdvanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response
Sanvito F, Kryukov I, Yao J, Teraishi A, Raymond C, Gao J, Miller C, Nghiemphu P, Lai A, Liau L, Patel K, Everson R, Eldred B, Prins R, Nathanson D, Salamon N, Cloughesy T, Ellingson B. Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF response. Journal Of Neuro-Oncology 2025, 173: 583-594. PMID: 40227555, PMCID: PMC12170782, DOI: 10.1007/s11060-025-05019-8.Peer-Reviewed Original ResearchCitationsAltmetric
2024
Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma
Oshima S, Yao J, Bobholz S, Nagaraj R, Raymond C, Teraishi A, Guenther A, Kim A, Sanvito F, Cho N, Eldred B, Connelly J, Nghiemphu P, Lai A, Salamon N, Cloughesy T, LaViolette P, Ellingson B. Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma. CNS Oncology 2024, 13: 2415285. PMID: 39535237, PMCID: PMC11562955, DOI: 10.1080/20450907.2024.2415285.Peer-Reviewed Original ResearchCitations